Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.

导出 LinkOut

翻译打印收藏纠错

作者： Fazila,Bunglawala ^[1] ; Rajith K R,Rajoli ^[1] ; Mark,Mirochnick ^[2] ; Andrew,Owen ^[1] ; Marco,Siccardi ^[1]

作者单位： Department of Molecular and Clinical Pharmacology, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK. ^[1] Boston University, Boston, MA, USA. ^[2]

主题词儿童(Child);HIV感染(HIV Infections);HIV整合酶抑制剂(HIV Integrase Inhibitors);杂环化合物, 3环(Heterocyclic Compounds, 3-Ring);人类(Humans);婴儿, 新生(Infant, Newborn);恶嗪类(Oxazines);哌嗪类(Piperazines);吡啶酮类(Pyridones)

DOI 10.1093/jac/dkz506

PMID 31860112

发布时间 2021-06-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The Journal of antimicrobial chemotherapy

2020年75卷3期

640-647页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.

The Journal of antimicrobial chemotherapy

相似文献

The Journal of antimicrobial chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.

The Journal of antimicrobial chemotherapy

相似文献

The Journal of antimicrobial chemotherapy

相关期刊

检索历史清除